This article presents a microcosting analysis of resources needed for the implementation and sustainment of the Massachusetts model evaluated in the PROUD trial.
Sean M. Murphy, PhD
Advertisement
Articles by Sean M. Murphy, PhD
The mean 24-week cost per participant was $5416 for extended-release injectable naltrexone (57% detoxification, 37% medication, 6% provider/patient) and $4148 for buprenorphine-naloxone (64% detoxification, 12% medication, 24% provider/patient).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5